Table VIII.

Co-expression of survivin and p53 in endometrial carcinoma according to stain intensity of immunopositive cells in relation to clinicopathological parameters.

Characteristics	Patients with survivin and p53 weak positive expression, n (%)	Patients with either survivin or p53 moderate positive expression, n (%)	Patients with survivin and p53 strong positive expression, n (%)	P-value
Age, years
<60	3 (23.1)	18 (35.3)	0 (0.0)	0.014
≥60	10 (76.9)	33 (64.7)	8 (100.0)
Histological type
Endometrioid	12 (92.3)	50 (98.0)	6 (75.0)	0.001
Clear cell and papillary serous	1 (7.7)	1 (2.0)	2 (25.0)
Clinical stage
I	10 (90.9)	41 (87.2)	2 (33.3)	0.032
II	1 (9.1)	5 (10.6)	3 (50.0)
III	0 (0.0)	1 (2.1)	1 (16.7)
Histological differentiation
G1	6 (46.2)	10 (19.6)	1 (12.5)	<0.001
G2	7 (53.8)	31 (60.8)	2 (25.0)
G3	0 (0.0)	10 (19.6)	5 (62.5)
Myometrial invasion
<1/2	6 (46.2)	20 (39.2)	1 (12.5)	0.274
≥1/2	7 (53.8)	31 (60.8)	7 (87.5)
Lymph-vascular space invasion
Yes	1 (14.3)	6 (18.2)	2 (25.0)	0.799
No	6 (85.7)	27 (81.8)	6 (75.0)
Fallopian tube and/or ovarian invasion
Yes	1 (20.0)	6 (27.3)	4 (66.7)	0.084
No	4 (80.0)	16 (72.7)	2 (33.3)
Tumoral necrosis
Yes	0 (0.0)	3 (10.3)	1 (14.3)	0.733
No	7 (100.0)	26 (89.7)	6 (85.7)

P<0.05, statistically significant results; 0.05<P<0.10, suggestive results.